Trial Profile

A Phase 1b/2, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zocilurtatug pelitecan (Primary)
Indications Gastric cancer; Large cell carcinoma; Malignant melanoma; Neuroendocrine carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors ZAI Lab

Most Recent Events

11 May 2026 Results presented in a Zai Lab Media Release.
11 May 2026 According to a Zai Lab media release, preliminary data from this study was presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 last month.
17 Apr 2026 Results presented in the Zai Lab Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com